#1 Clinical Trials Search in Europe

Allergenic Extract Of Olea Europaea Pollen Polymerized With Glutaraldehyde

Recent clinical trials are investigating the use of Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde as a potential treatment for allergies, particularly those related to olive pollen. These studies aim to assess the efficacy and safety of this extract when administered as subcutaneous immunotherapy for patients suffering from moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma.

Table of Contents

What is Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde?

Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde is a medication used to treat allergies caused by olive tree pollen. It’s also known by other names such as “Modified allergen extract of olive pollen polymerized with glutaraldehyde” or “T517”[1]. This medication is a type of allergen immunotherapy, which means it’s designed to help your body become less sensitive to olive pollen over time.

How Does It Work?

This medication works by exposing your immune system to small, controlled amounts of olive pollen allergens. The allergens in this extract have been modified (or “polymerized”) with a substance called glutaraldehyde. This modification helps to reduce the risk of severe allergic reactions while still allowing your immune system to build up tolerance to the allergen[1].

Over time, regular exposure to these modified allergens can help your immune system become less reactive to olive pollen. This can lead to a reduction in allergy symptoms when you’re exposed to olive pollen in your environment.

What Conditions Does It Treat?

This medication is primarily used to treat moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by olive pollen[1]. Let’s break down these terms:

  • Allergic rhinitis: This is inflammation of the inside of the nose caused by an allergen, such as pollen. Symptoms can include sneezing, runny nose, and nasal congestion.
  • Rhinoconjunctivitis: This condition affects both the nose and the eyes. In addition to nasal symptoms, it can cause itchy, red, and watery eyes.

The medication can be used in patients with or without mild-to-moderate asthma, as long as the asthma is well-controlled[1].

How Is It Administered?

This medication is typically administered as a subcutaneous injection, which means it’s injected just under the skin[2]. The treatment usually follows a specific schedule:

  1. An initial phase where the dose is gradually increased
  2. A maintenance phase where you receive regular injections to maintain the effect

The exact dosing schedule can vary, but treatment may continue for several months or even years. It’s important to follow your doctor’s instructions carefully and attend all scheduled appointments.

Effectiveness

Clinical trials are currently underway to assess the effectiveness of this treatment. Researchers are looking at several measures to determine how well it works, including[1]:

  • Reduction in allergy symptoms
  • Decreased need for allergy medications
  • Improvement in quality of life
  • Changes in immune system markers (like specific antibodies)

One of the main goals is to reduce what’s called the “Combined Symptom and Medication Score” (CSMS) during the olive pollen season. This score takes into account both how severe a person’s allergy symptoms are and how much medication they need to control those symptoms[1].

Safety and Side Effects

As with any medical treatment, there are potential side effects and safety considerations. Common side effects of allergen immunotherapy can include[1]:

  • Reactions at the injection site (redness, swelling, itching)
  • Mild allergic reactions (such as increased allergy symptoms)

In rare cases, more severe allergic reactions can occur. That’s why this treatment is always administered under medical supervision, and you’ll be asked to stay at the clinic for a short time after each injection[1].

It’s important to note that this treatment is not suitable for everyone. For example, it may not be recommended for people with severe or uncontrolled asthma, certain immune system disorders, or those taking specific medications[1].

Ongoing Research

Clinical trials are currently being conducted to further evaluate the effectiveness and safety of this treatment. These studies are looking at different doses of the medication and comparing it to a placebo (a treatment with no active ingredients)[1][2].

Researchers are also studying how this treatment might be combined with other allergen extracts, such as grass pollen, for people who are allergic to multiple types of pollen[2].

As research continues, we may learn more about the best ways to use this treatment and who is most likely to benefit from it.

Aspect Details
Treatment Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde
Administration Method Subcutaneous injection
Target Condition Moderate to severe allergic rhinitis/rhinoconjunctivitis due to olive pollen
Study Population Adults aged 18-65 (some studies include patients as young as 12)
Primary Outcome Measure Combined Symptom and Medication Score (CSMS) during peak pollen season
Secondary Outcomes Quality of life, symptom-free days, immunological parameters, safety assessment
Study Design Randomized, double-blind, placebo-controlled
Treatment Duration Varies by study, typically several months to a year

FAQ

  • What is the main purpose of these clinical trials? The main purpose is to evaluate the effectiveness and safety of Allergenic Extract of Olea Europaea Pollen Polymerized with Glutaraldehyde as a treatment for moderate to severe olive pollen allergies, including allergic rhinitis and rhinoconjunctivitis.
  • Who can participate in these trials? Participants are generally adults aged 18-65 with a confirmed history of moderate to severe allergic rhinitis or rhinoconjunctivitis due to olive pollen. Some trials also include patients with controlled mild to moderate asthma.
  • How is the treatment administered? The treatment is administered through subcutaneous injections, which means it's injected just under the skin.
  • What are the main outcomes being measured in these trials? The trials are measuring various outcomes, including changes in allergy symptoms and medication use, quality of life improvements, and safety of the treatment. Some trials use a Combined Symptom and Medication Score (CSMS) as a primary measure of effectiveness.
  • Are there any risks associated with participating in these trials? As with any clinical trial, there may be risks involved. These can include potential allergic reactions to the treatment. However, the trials are designed to monitor safety closely, and participants are carefully screened for eligibility to minimize risks.

Ongoing Clinical Trials on Allergenic Extract Of Olea Europaea Pollen Polymerized With Glutaraldehyde

  • Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

    Not recruiting

    3 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of Allergenic Extract of Olea Europaea Pollen for Patients with Moderate-to-Severe Olive Pollen Allergy

    Not recruiting

    4 1 1
    Investigated drugs:
    Spain

Glossary

  • Allergenic Extract: A substance derived from a source of allergens (in this case, olive pollen) that is used to diagnose or treat allergies.
  • Olea Europaea: The scientific name for the olive tree, which produces pollen that can cause allergies in some people.
  • Polymerized with Glutaraldehyde: A process where the allergen extract is chemically modified to reduce its ability to cause severe allergic reactions while maintaining its therapeutic effects.
  • Subcutaneous Immunotherapy (SCIT): A form of allergy treatment where small amounts of allergens are injected under the skin to help the body build tolerance over time.
  • Allergic Rhinitis: An allergic reaction affecting the nose, often causing sneezing, runny nose, and nasal congestion.
  • Rhinoconjunctivitis: A combination of rhinitis (nasal symptoms) and conjunctivitis (eye symptoms) caused by allergies.
  • Combined Symptom and Medication Score (CSMS): A measure used in allergy studies to assess the severity of symptoms and the amount of medication needed to control them.
  • Peak Olive Pollen Period (POPP): The time of year when olive pollen levels are at their highest, typically used as a key period for assessing allergy treatments.
  • Forced Expiratory Volume (FEV1): A measure of lung function, specifically how much air a person can exhale in one second.
  • Titrated Nasal Provocation Test (tNPT): A test used to diagnose and assess nasal allergies by exposing the nose to increasing amounts of an allergen.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-allergenic-extract-of-olea-europaea-pollen-for-patients-with-moderate-to-severe-olive-pollen-allergy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-olive-pollen-allergy-vaccine-for-patients-with-allergic-rhinitis-or-asthma/